US FDA’s Three Review Speeds: Standard, Priority – And Oncology
Executive Summary
FDA’s oncology review team likes to do things its own way – and at its own hyper fast pace.
You may also be interested in...
US FDA Drug Review Goals Should Be Faster In PDUFA VII, Industry Negotiators Propose
Sponsor representatives also want postmarketing discussions moved to earlier in the assessment cycle.
Breakthroughs, Orphans Hit High Notes As US FDA’s 2020 Novel Approvals Play A Familiar Tune
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.
US FDA’s Fastest Approvals Concentrate In Oncology, Infectious Disease
The agency’s quickest approvals include two in 2020 – Gilead’s Veklury and Seattle Genetics’ Tukysa – but two 1990s AIDS drugs are at the top of the list.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: